Insider activities archive   |   Recent insider buys   |   Top 10 insider buys   |   Search Insiders!



Insider Trading: ACORDA THERAPEUTICS INC

Monthly summaries of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of ACORDA THERAPEUTICS INC in the last 24 months are illustrated in figures 1 and 2. Table 1 shows the monthly insider trading data of ACORDA THERAPEUTICS INC since year 2005. Table 2 shows the detailed insider transactions of ACORDA THERAPEUTICS INC since 2005. The reporting company's ticker symbol is ACOR. The reporting company's CIK number is 1008848.
1 year chart,   5 day chart,   1 day chart.

The total value of stock buying since 2005 is $2,000,004. The total value of stock sales is $55,117,294. The total value of stock exercises is $564,701.


Figure 1. Monthly insider transaction values at ACORDA THERAPEUTICS INC (ACOR) in the past 24 months. The trade values of insider stock buys, sales, and option exercises are in logarithmic scale as shown on the right axis labels. The detailed monthly and daily insider transactions are listed in the 2 tables below.

  • 07

  • 08

  • 09

  • 10

  • 11

  • 12

  • 01 2007

  • 02

  • 03

  • 04

  • 05

  • 06

  • 07

  • 08

  • 09

  • 10

  • 11

  • 12

  • 01 2008

  • 02

  • 03

  • 04

  • 05

  • 06

  • $18,313k

    $1,831k

    $183k

    $18k

  • Buy
  • Sale
  • Option Exercise

Figure 2. Average prices of insider buys, sales, and option exercises at ACORDA THERAPEUTICS INC (ACOR) in the past 24 months. See table 2 for insider transaction details.

  • 07

  • 08

  • 09

  • 10

  • 11

  • 12

  • 01 2007

  • 02

  • 03

  • 04

  • 05

  • 06

  • 07

  • 08

  • 09

  • 10

  • 11

  • 12

  • 01 2008

  • 02

  • 03

  • 04

  • 05

  • 06

  • $31.26

    $23.45

    $15.63

    $7.82



Table 1. Monthly summaries of insider stock purchases, sales, and option exercises for ACORDA THERAPEUTICS INC (ACOR).
Trading Period
year-month  
Insider Buying     
Shares               Value ($)
Insider Sales     
Shares               Value ($)
Option Exercises     
Shares               Value ($)
2008-06 0 0 482,612 14,881,767 141,390 487,304
2008-05 0 0 2,425 46,458 0 0
2008-04 0 0 3,586 65,953 0 0
2008-03 0 0 19,400 347,862 0 0
2008-02 0 0 106,912 2,333,655 4,487 11,666
2008-01 0 0 714,118 18,313,993 7,000 18,200
2007-12 0 0 24,332 515,880 7,000 18,200
2007-11 0 0 9,293 169,853 0 0
2007-10 0 0 6,795 137,163 4,487 11,666
2007-09 0 0 18,440 308,785 0 0
2007-08 0 0 131,942 2,269,362 6,410 16,666
2007-07 0 0 7,500 132,690 0 0
2007-06 0 0 156,755 2,914,386 0 0
2007-05 0 0 10,983 267,901 0 0
2007-04 0 0 8,383 164,884 0 0
2007-03 0 0 25,323 506,914 0 0
2007-02 0 0 24,719 530,738 0 0
2007-01 0 0 20,141 326,576 0 0
2006-12 0 0 24,897 445,667 641 999
2006-11 0 0 293,896 4,787,604 0 0
2006-10 0 0 346,002 5,649,203 0 0
2006-02 333,334 2,000,004 0 0 0 0

Table 2. Detailed insider stock purchases, sales, and option exercises for ACORDA THERAPEUTICS INC (ACOR)
  Trade Date   Insider Name Trade Type     Shares       Price ($)   Value ($)
2008-06-13 Phillips Barclay A Sale 235,000 30.54 7,177,006
2008-06-12 Blight Andrew (Chief Scientific Officer) Sale 28,700 30.98 892,157
2008-06-12 Blight Andrew (Chief Scientific Officer) Option Exercise 29,200 2.60 75,920
2008-06-12 Lawrence David (Chief Financial Officer) Sale 7,000 31.02 217,133
2008-06-12 Lawrence David (Chief Financial Officer) Option Exercise 7,000 5.85 40,950
2008-06-11 Wasman Jane (Exec VP, General Counsel & Sec) Sale 3,500 31.61 110,623
2008-06-11 Wasman Jane (Exec VP, General Counsel & Sec) Option Exercise 3,500 5.85 20,475
2008-06-11 Blight Andrew (Chief Scientific Officer) Sale 800 31.54 25,228
2008-06-11 Blight Andrew (Chief Scientific Officer) Option Exercise 800 2.60 2,080
2008-06-05 Blight Andrew (Chief Scientific Officer) Sale 20,000 32.10 637,628
2008-06-05 Blight Andrew (Chief Scientific Officer) Option Exercise 20,000 2.60 52,000
2008-06-05 Cohen Ron (President and CEO) Sale 50,000 31.89 1,586,664
2008-06-05 Cohen Ron (President and CEO) Option Exercise 50,000 2.60 130,000
2008-06-04 Lawrence David (Chief Financial Officer) Sale 33,106 29.67 980,662
2008-06-04 Lawrence David (Chief Financial Officer) Option Exercise 30,890 5.37 165,879
2008-05-12 Wasman Jane (Exec VP, General Counsel & Sec) Sale 2,425 19.16 46,458
2008-04-07 Blight Andrew (Chief Scientific Officer) Sale 3,586 18.39 65,953
2008-03-10 Blight Andrew (Chief Scientific Officer) Sale 4,000 17.93 71,705
2008-03-10 Cohen Ron (President and CEO) Sale 8,100 17.85 145,328
2008-03-10 Lawrence David (Chief Financial Officer) Sale 1,800 17.34 31,215
2008-02-19 Panem Sandra Phd Sale 83,000 21.50 1,784,500
2008-02-15 Blight Andrew (Chief Scientific Officer) Sale 4,487 23.38 104,917
2008-02-15 Blight Andrew (Chief Scientific Officer) Option Exercise 4,487 2.60 11,666
2008-02-14 Panem Sandra Phd Sale 17,000 22.85 388,484
2008-02-11 Wasman Jane (Exec VP, General Counsel & Sec) Sale 2,425 22.99 55,754
2008-01-23 Wasman Jane (Exec VP, General Counsel & Sec) Sale 2,425 22.66 54,953
2008-01-23 Lawrence David (Chief Financial Officer) Sale 1,107 22.96 25,413
2008-01-15 Blight Andrew (Chief Scientific Officer) Sale 3,586 23.04 82,627
2008-01-14 Holman Wayne George (10% Owner) Sale 700,000 25.68 17,976,000
2008-01-11 Lawrence David (Chief Financial Officer) Sale 7,000 25.00 175,000
2008-01-11 Lawrence David (Chief Financial Officer) Option Exercise 7,000 2.60 18,200
2007-12-27 Lawrence David (Chief Financial Officer) Sale 7,000 23.08 161,589
2007-12-27 Lawrence David (Chief Financial Officer) Option Exercise 7,000 2.60 18,200
2007-12-21 Wasman Jane (Exec VP, General Counsel & Sec) Sale 2,425 20.56 49,851
2007-12-21 Lawrence David (Chief Financial Officer) Sale 1,107 20.57 22,768
2007-12-10 Blight Andrew (Chief Scientific Officer) Sale 4,000 20.38 81,506
2007-12-10 Cohen Ron (President and CEO) Sale 8,000 20.43 163,448
2007-12-10 Lawrence David (Chief Financial Officer) Sale 1,800 20.40 36,718
2007-11-21 Lawrence David (Chief Financial Officer) Sale 1,003 17.15 17,201
2007-11-15 Blight Andrew (Chief Scientific Officer) Sale 5,865 18.27 107,153
2007-11-12 Wasman Jane (Exec VP, General Counsel & Sec) Sale 2,425 18.76 45,499
2007-10-23 Wasman Jane (Exec VP, General Counsel & Sec) Sale 2,425 20.13 48,818
2007-10-23 Lawrence David (Chief Financial Officer) Sale 1,004 20.13 20,211
2007-10-15 Blight Andrew (Chief Scientific Officer) Sale 3,366 20.24 68,134
2007-10-15 Blight Andrew (Chief Scientific Officer) Option Exercise 4,487 2.60 11,666
2007-09-26 Wasman Jane (Exec VP, General Counsel & Sec) Sale 2,425 18.79 45,563
2007-09-26 Lawrence David (Chief Financial Officer) Sale 2,008 18.77 37,682
2007-09-12 Lawrence David (Chief Financial Officer) Sale 2,007 15.98 32,076
2007-09-10 Blight Andrew (Chief Scientific Officer) Sale 4,000 16.05 64,191
2007-09-10 Cohen Ron (President and CEO) Sale 8,000 16.16 129,273
2007-08-17 Blight Andrew (Chief Scientific Officer) Sale 3,044 18.05 54,944
2007-08-17 Blight Andrew (Chief Scientific Officer) Option Exercise 6,410 2.60 16,666
2007-08-14 Cohen Ron (President and CEO) Sale 26,000 16.95 440,575
2007-08-13 Cohen Ron (President and CEO) Sale 26,000 16.74 443,044
2007-08-10 Wasman Jane (Exec VP, General Counsel & Sec) Sale 2,425 16.99 41,205
2007-08-10 Cohen Ron (President and CEO) Sale 26,000 17.00 441,979
2007-08-09 Cohen Ron (President and CEO) Sale 26,000 17.78 462,149
2007-07-02 Fisher Mary (Chief Operating Officer) Sale 7,500 17.69 132,690
2007-06-15 Lawrence David (Chief Financial Officer) Sale 2,007 18.48 37,086
2007-06-15 Panem Sandra Phd Sale 23,708 18.48 438,178
2007-06-12 Blight Andrew (Chief Scientific Officer) Sale 500 31.05 15,525
2007-06-08 Blight Andrew (Chief Scientific Officer) Sale 3,040 18.50 56,240
2007-06-08 Panem Sandra Phd Sale 120,000 18.50 2,220,000
2007-06-01 Fisher Mary (Chief Operating Officer) Sale 7,500 19.65 147,357
2007-05-23 Lawrence David (Chief Financial Officer) Sale 883 24.20 21,371
2007-05-10 Wasman Jane (Exec VP, General Counsel & Sec) Sale 2,600 24.76 64,370
2007-05-01 Fisher Mary (Chief Operating Officer) Sale 7,500 24.29 182,160
2007-04-23 Lawrence David (Chief Financial Officer) Sale 883 24.05 21,236
2007-04-02 Fisher Mary (Chief Operating Officer) Sale 7,500 19.15 143,648
2007-03-22 Lawrence David (Chief Financial Officer) Sale 11,882 19.63 233,212
2007-03-01 Fisher Mary (Chief Operating Officer) Sale 7,500 20.95 157,096
2007-02-27 Panem Sandra Phd Sale 8,678 23.42 203,242
2007-02-23 Lawrence David (Chief Financial Officer) Sale 5,941 23.50 139,633
2007-02-12 Wasman Jane (Exec VP, General Counsel & Sec) Sale 2,600 21.46 55,798
2007-02-01 Fisher Mary (Chief Operating Officer) Sale 7,500 17.61 132,065
2007-01-23 Lawrence David (Chief Financial Officer) Sale 5,941 17.57 104,388
2007-01-03 Fisher Mary (Chief Operating Officer) Sale 7,500 15.50 117,226
2006-12-20 Lawrence David (Chief Financial Officer) Sale 5,941 15.82 93,986
2006-12-11 Blight Andrew (Chief Scientific Officer) Sale 2,500 16.93 42,316
2006-12-11 Lawrence David (Chief Financial Officer) Sale 1,365 17.00 23,210
2006-12-08 Young Wise Option Exercise 641 1.56 999
2006-12-01 Fisher Mary (Chief Operating Officer) Sale 7,500 18.96 142,215
2006-12-01 Cohen Ron (President and CEO) Sale 7,591 18.96 143,940
2006-11-30 Blight Andrew (Chief Scientific Officer) Sale 641 19.52 12,509
2006-11-20 Lawrence David (Chief Financial Officer) Sale 5,058 18.72 96,349
2006-11-13 Pinney Mark R E Sale 15,713 14.94 234,699
2006-11-10 Wasman Jane (Exec VP, General Counsel & Sec) Sale 4,851 15.21 73,765
2006-11-07 Wasman Jane (Exec VP, General Counsel & Sec) Sale 15,000 15.40 232,644
2006-11-07 Blight Andrew (Chief Scientific Officer) Sale 30,000 15.48 464,749
2006-11-06 Wasman Jane (Exec VP, General Counsel & Sec) Sale 22,000 16.06 353,246
2006-11-06 Blight Andrew (Chief Scientific Officer) Sale 25,000 16.07 401,828
2006-11-06 Fisher Mary (Chief Operating Officer) Sale 40,000 16.07 642,857
2006-11-06 Lawrence David (Chief Financial Officer) Sale 14,853 16.07 238,662
2006-11-01 Cohen Ron (President & CEO) Sale 50,000 17.05 857,093
2006-10-16 Pinney Mark R E (Director) Sale 158,781 16.50 2,600,991
2006-10-16 Cohen Ron (President & CEO) Sale 50,000 16.39 820,839
2006-02-15 Panem Sandra Phd (Director) Purchase 41,667 6.00 250,002
2006-02-15 Steinmetz Michael (Director) Purchase 166,667 6.00 1,000,002
2006-02-15 Fleming Standish (Director) Purchase 125,000 6.00 750,000

Insider trading activities including stock purchases, stock sales, and option exercises listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of ACORDA THERAPEUTICS INC (symbol ACOR, CIK number 1008848) see the Securities and Exchange Commission (SEC) website.

© 2005-2008, insider-monitor.com. All rights reserved.